156 related articles for article (PubMed ID: 28426742)
1. Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei.
Saarinen L; Nummela P; Thiel A; Lehtonen R; Järvinen P; Järvinen H; Aaltonen LA; Lepistö A; Hautaniemi S; Ristimäki A
PLoS One; 2017; 12(4):e0174898. PubMed ID: 28426742
[TBL] [Abstract][Full Text] [Related]
2. The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review.
Lin YL; Ma R; Li Y
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2179-2188. PubMed ID: 32700107
[TBL] [Abstract][Full Text] [Related]
3. Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.
Saarinen L; Nummela P; Leinonen H; Heiskanen A; Thiel A; Haglund C; Lepistö A; Satomaa T; Hautaniemi S; Ristimäki A
Mol Cell Proteomics; 2018 Nov; 17(11):2107-2118. PubMed ID: 30072579
[TBL] [Abstract][Full Text] [Related]
4. The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
Wang B; Yao J; Ma R; Liu D; Lu Y; Shi G; An L; Xia A; Chen F; Pang S; Zhai X; Liu G; Chen S; Xu M; Song L; Xu H
Int J Cancer; 2021 Apr; 148(8):2036-2047. PubMed ID: 33403690
[TBL] [Abstract][Full Text] [Related]
5. Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
Gleeson EM; Feldman R; Mapow BL; Mackovick LT; Ward KM; Morano WF; Rubin RR; Bowne WB
Am J Clin Oncol; 2018 Aug; 41(8):777-783. PubMed ID: 28263231
[TBL] [Abstract][Full Text] [Related]
6. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women.
Szych C; Staebler A; Connolly DC; Wu R; Cho KR; Ronnett BM
Am J Pathol; 1999 Jun; 154(6):1849-55. PubMed ID: 10362811
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing identified the genetic origin of a mucinous neoplasm in a mature cystic teratoma.
Choi YJ; Lee SH; Kim MS; Jung SH; Hur SY; Chung YJ; Lee SH
Pathology; 2016 Jun; 48(4):372-6. PubMed ID: 27114374
[TBL] [Abstract][Full Text] [Related]
9. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth.
Dilly AK; Song X; Zeh HJ; Guo ZS; Lee YJ; Bartlett DL; Choudry HA
Transl Res; 2015 Oct; 166(4):344-54. PubMed ID: 25890193
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.
Pengelly RJ; Rowaiye B; Pickard K; Moran B; Dayal S; Tapper W; Mirnezami A; Cecil T; Mohamed F; Carr N; Ennis S
J Mol Diagn; 2018 Sep; 20(5):635-642. PubMed ID: 29936255
[TBL] [Abstract][Full Text] [Related]
13. Strategies for Preventing Pseudomyxoma Peritonei After Resection of a Mucinous Neoplasm of the Appendix.
Honoré C; Caruso F; Dartigues P; Benhaim L; Chirica M; Goéré D; Elias D
Anticancer Res; 2015 Sep; 35(9):4943-7. PubMed ID: 26254392
[TBL] [Abstract][Full Text] [Related]
14. Peptide vaccine targeting mutated
Flatmark K; Torgunrud A; Fleten KG; Davidson B; Juul HV; Mensali N; Lund-Andersen C; Inderberg EM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711663
[TBL] [Abstract][Full Text] [Related]
15. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
Shetty S; Thomas P; Ramanan B; Sharma P; Govindarajan V; Loggie B
J Surg Res; 2013 Mar; 180(1):97-103. PubMed ID: 23199549
[TBL] [Abstract][Full Text] [Related]
16. Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei.
Lin YL; Zhu JQ; Ma RQ; Meng W; Wang ZY; Li XB; Ma R; Wu HL; Xu HB; Gao Y; Li Y
Mol Cancer Res; 2024 Jan; 22(1):70-81. PubMed ID: 37768171
[TBL] [Abstract][Full Text] [Related]
17. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
18. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
19. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
20. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
